Interview With Gilles Salles, MD, PhD: Novel Treatments in DLBCL

Interview With Shani Irby, ANP-BC: CAR T-Cell Therapy in DLBCL

Interview With Shani Irby, ANP-BC: Relapsed DLBCL and the Role of Autologous Stem Cell Transplant

Welcome to the JADPRO Diffuse Large B-Cell Lymphoma Resource Center! We've curated the most important information, education, and cutting-edge research on this disease state and created our own original resources to empower your practice. We're excited to provide this new offering, and we hope you and your colleagues find it valuable in helping your patients navigate DLBCL diagnosis, treatment, and survivorship. Take a look around, and send us your feedback at editor@advancedpractitioner.com

Ashley Ames, MSN, RN, FNP-BC, OCN
Oncology Nurse Practitioner
Memorial Sloan Kettering Cancer Center

Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

Scientific Reports

Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma

Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma

Safety and efficacy of subcutaneous rituximab in previously untreated patients with CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from an Italian phase IIIb study

DLBCL Resource Center

Interview With Gilles Salles, MD, PhD: Novel Treatments in DLBCL

Lymphoma Research Foundation

COVID-19 and Aggressive Lymphoma: FAQ

COVID-19 and Vaccines for the Immunocompromised: FAQ

NCCN Guidelines on Diffuse Large B-Cell Lymphoma

DLBCL Trials on Clinicaltrials.gov

Journal of Clinical Oncology

Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: International metabolic prognostic index

Blood Cancer Journal

Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

Scientific Reports

Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma

U.S. Food and Drug Administration

FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma

Cure

Targeted therapies shake up the DLBCL treatment paradigm, expert says

Transplantation and Cellular Therapy

Assessment of salvage regimens post CAR-T cell therapy for patients with diffuse large B-cell lymphoma

Cell Therapy Next

CAR-T poised to create ‘paradigm shift’ in non-Hodgkin lymphoma

Blood Cancer Journal

Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma

Oncology

Current Frontline Treatment of Diffuse Large B-Cell Lymphoma

Advances in Hematology

Safety and efficacy of subcutaneous rituximab in previously untreated patients with CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from an Italian phase IIIb study

Fast Facts #12: Long-Term Survivorship